Skip to main content
SpringerLink
Log in

Pediatric Asthma Controller Therapy

  • Review Article
  • Published:
Pediatric Drugs Aims and scope Submit manuscript

Abstract

The treatment of children with asthma has historically relied upon expert opinion using data extrapolated from adult studies. Over the past few years, landmark studies have been completed providing healthcare professionals with evidence on which a reasonable approach can be made for children suffering from this common and serious disease. Asthmatic phenotype in children, unlike adults, tends to differ according to age, which must be taken into account as well as triggers, severity, and level of control. The care of the child with asthma is complex, but accumulating data have demonstrated that we are on the right path for optimizing control while reducing the burden of side effects.

The newest Global Initiative for Asthma (GINA) guidelines, as well as recent updates from the landmark CAMP (Childhood Asthma Management Program) study and information from the PACT (Pediatric Asthma Control Trial) and budesonide/formoterol controller and reliever studies, along with recent comparisons of higher dose inhaled corticosteroids (ICS), and ICS/long-acting β2-adrenoceptor agonist (LABA) combination and leukotriene receptor antagonist (LTRA) therapies in children have clarified a few of the big questions in pediatric asthma. For children with asthma aged 5 years and older, the CAMP trial demonstrated that regular use of ICS reduces the frequency of symptoms; however, height was adversely affected and there is no evidence for altering the natural history of asthma. In patients aged 6 years and over whose asthma is uncontrolled on ICS alone, combination therapy with ICS and a LABA has been recently compared with the use of higher dose ICS and the addition of an LTRA in pediatric patients. The addition of a LABA statistically will be of most benefit; however, some children will have optimal control with doubling the baseline dose of ICS or addition of an LTRA. Use of budesonide/formoterol as a controller and reliever therapy extends the time to first exacerbation versus contemporary use of this medication in patients aged 4 years and older. Ciclesonide, a newer ICS, has demonstrated acceptable efficacy but has the added benefit of not affecting growth. Certainly, with mounting evidence, the care-map in pediatric asthma control is becoming clearer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Similar content being viewed by others

References

  1. NHLBI/WHO Workshop Report: global strategy for asthma diagnosis and Management. Washington, DC: US Department of Health and Human Services, 1995: NIH Publication No. 95-3659

  2. Global Initiative for Asthma guidelines [online]. Available from URL: http://www.ginasthma.org [Accessed 2010 Aug 14]

  3. Global Initiative for Asthma (GINA). 2005 update: workshop report, global strategy for asthma management and prevention (2005) [online]. Available from URL: http://www.ginasthma.org/GuidelineItem.asp?intId=1169 [Accessed 2010 Nov 22]

  4. Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008 Jan; 31(1): 143–78

    Article  PubMed  CAS  Google Scholar 

  5. The Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med 2000 Oct 12; 343(15): 1054–63

    Article  Google Scholar 

  6. Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med 2000 Oct 12; 343(15): 1064–9

    Article  PubMed  CAS  Google Scholar 

  7. Strunk RC, Sternberg AL, Szefler SJ, et al. Long-term budesonide or nedocromil treatment, once discontinued, does not alter the course of mild to moderate asthma in children and adolescents. J Pediatr 2009 May; 154(5): 682–7

    Article  PubMed  CAS  Google Scholar 

  8. Kelly HW, Van Natta ML, Covar RA, et al. Effect of long-term corticosteroid use on bone mineral density in children: a prospective longitudinal assessment in the childhood Asthma Management Program (CAMP) study. Pediatrics 2008 Jul; 122(1): e53–61

    Article  PubMed  Google Scholar 

  9. Sorkness CA, Lemanske Jr RF, Mauger DT, et al. Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: the Pediatric Asthma Controller Trial. J Allergy Clin Immunol 2007 Jan; 119(1): 64–72

    Article  PubMed  Google Scholar 

  10. Jat GC, Mathew JL, Singh M. Treatment with 400 microg of inhaled budesonide versus 200 microg of inhaled budesonide and oral montelukast in children with moderate persistent asthma: randomized controlled trial. Ann Allergy Asthma Immunol 2006 Sep; 97(3): 397–401

    Article  PubMed  CAS  Google Scholar 

  11. Joos S, Miksch A, Szecsenyi J, et al. Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review. Thorax 2008 May; 63(5): 453–62

    Article  PubMed  CAS  Google Scholar 

  12. Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997 Nov 13; 337(20): 1405–11

    Article  PubMed  CAS  Google Scholar 

  13. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study. Am J Respir Crit Care Med 2004 Oct 15; 170(8): 836–44

    Article  PubMed  Google Scholar 

  14. de Blic J, Ogorodova L, Klink R, et al. Salmeterol/fluticasone propionate versus double dose fluticasone propionate on lung function and asthma control in children. Pediatr Allergy Immunol 2009 Dec; 20(8): 763–71

    Article  PubMed  Google Scholar 

  15. van Noord JA, Smeets JJ, Raaijmakers JA, et al. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. Eur Respir J 1996; 9(8): 1684–8

    Article  PubMed  Google Scholar 

  16. O’Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005 Jan 15; 171(2): 129–36

    Article  PubMed  Google Scholar 

  17. Bisgaard H, Le RP, Bjamer D, et al. Budesonide/formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma. Chest 2006 Dec; 130(6): 1733–43

    Article  PubMed  CAS  Google Scholar 

  18. Cates CJ, Cates MJ. Regular treatment with salmeterol for chronic asthma: serious adverse events. Cochrane Database Syst Rev 2008; (3): CD006363

    Google Scholar 

  19. Cates CJ, Cates MJ, Lasserson TJ. Regular treatment with formoterol for chronic asthma: serious adverse events. Cochrane Database Syst Rev 2008; (4): CD006923

    Google Scholar 

  20. Cates CJ, Lasserson TJ, Jaeschke R. Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events. Cochrane Database Syst Rev 2009; (2): CD006924

    Google Scholar 

  21. Cates CJ, Lasserson TJ, Jaeschke R. Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events. Cochrane Database Syst Rev 2009; (3): CD006922

    Google Scholar 

  22. Lemanske Jr RF, Mauger DT, Sorkness CA, et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med 2010; 362(11): 975–85

    Article  PubMed  CAS  Google Scholar 

  23. Agertoft L, Pedersen S. Short-term lower-leg growth rate and urine cortisol excretion in children treated with ciclesonide. J Allergy Clin Immunol 2005 May; 115(5): 940–5

    Article  PubMed  CAS  Google Scholar 

  24. Agertoft L, Pedersen S. Lower-leg growth rates in children with asthma during treatment with ciclesonide and fluticasone propionate. Pediatr Allergy Immunol 2010 Feb; 21 (1 Pt II): e199–205

    Article  PubMed  Google Scholar 

  25. von Berg A, Engelstatter R, Minic P, et al. Comparison of the efficacy and safety of ciclesonide 160 microg once daily versus budesonide 400 microg once daily in children with asthma. Pediatr Allergy Immunol 2007 Aug; 18(5): 391–400

    Article  Google Scholar 

  26. Pedersen S, Garcia Garcia ML, Manjra A, et al. A comparative study of inhaled ciclesonide 160 microg/day and fluticasone propionate 176 microg/day in children with asthma. Pediatr Pulmonol 2006 Oct; 41(10): 954–61

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Dr Anselmo has no financial interest in the products discussed but has served at a single advisory meeting for Nycomed and has received an honorarium from Merck-Frost as an invited speaker. No sources of funding were used to assist in the preparation of this review.

Author information

Authors and Affiliations

  1. Division of Respiratory Medicine, Alberta Children’s Hospital, Calgary, Alberta, Canada

    Mark Anselmo (Associate Professor)

Authors
  1. Mark Anselmo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark Anselmo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Anselmo, M. Pediatric Asthma Controller Therapy. Pediatr-Drugs 13, 11–17 (2011). https://doi.org/10.2165/11533730-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11533730-000000000-00000

Keywords

Search

Navigation